Posted inCardiology Diabetes & Endocrinology news
Oral Semaglutide and Cardiovascular Risk Factor Changes in High-Risk Type 2 Diabetes
Oral semaglutide improved multiple cardiovascular risk factors in high-risk type 2 diabetes, including HbA1c, weight, systolic blood pressure, inflammation, and some lipid measures, with benefits sustained over nearly four years.

